SERNYSEPharmaceutical PreparationsFiscal year ends December 31
Serina Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.65−0.07 (-4.07%)
Close on Oct 19, 2026
- Market cap
- $27.04M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.16 (−65.68%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Serina Therapeutics, Inc. grew revenue 132.1% to $130.00K over fiscal 2025. Free cash flow was -$21.20M.
Revenue
$130.00K
+132.1% vs. a year earlier
Operating income
-$24.02M
FY2025
Free cash flow
-$21.20M
TTM Q2 2026
EPS, diluted
-$1.90
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $27.04M
- P/E ratio
- –
- Price to sales
- 207.96
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -78.42%
Fundamentals
- Revenue
- $130.00K
- Net income
- -$21.18M
- EPS, diluted
- -$1.90
- Free cash flow
- -$21.20M
- Diluted shares
- 16M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
–
Net income
-$21.18M
EPS, diluted
-$1.90
Free cash flow
-$21.20M
Reported periodTrailing twelve months